Asset profile
Anifrolumab
Monoclonal antibody
Evidence outlook
Approved: Systemic Lupus Erythematosus
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 7 same-class, 54 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Anifrolumab: this drug | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | ||
| Peginterferon Beta-1a (Plegridy) | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | ||
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2 | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | ||
| APG-2575(Lisaftoclax ) | Phase 3 | Small molecule | BCL-2 | ||
| AZD0120 | Phase 3 | Cell therapy | BCMA / CD19 |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (4)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
2028 (4)
January 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (3)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
April 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
2032 (1)
December 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.